Fulcrum Therapeutics reported earnings of -$ 0.11 per FULC share on Nov 12, 2026, falling short of analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.11 |
| Earnings Per Share (Surprise) | -$ 0.11 ($ 0.00) |
| Last Year's EPS | -$ 0.30 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, Fulcrum Therapeutics beat analysts’ expectations 19 times and fell short of expectations 9 time(s). Fulcrum Therapeutics reported earnings per share of -$ 0.11 in the last report falling to reach an estimated EPS of -$ 0.11 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.11 | -$ 0.11 | -$ 0.31 | |
| Jul 30, 2026 | -$ 0.24 | -$ 0.34 | -$ 0.28 | |
| Apr 27, 2026 | -$ 0.31 | -$ 0.25 | -$ 0.28 | |
| Feb 24, 2026 | -$ 0.31 | -$ 0.31 | -$ 0.31 | |
| Oct 29, 2025 | -$ 0.29 | -$ 0.31 | -$ 0.35 | |
| Jul 29, 2025 | -$ 0.29 | -$ 0.28 | $ 0.87 | |
| May 1, 2025 | -$ 0.29 | -$ 0.28 | -$ 0.43 | |
| Feb 25, 2025 | -$ 0.28 | -$ 0.31 | -$ 0.40 | |
| Nov 13, 2024 | -$ 0.41 | -$ 0.35 | -$ 0.39 | |
| Jul 31, 2024 | -$ 0.01 | $ 0.87 | -$ 0.38 | |
| May 13, 2024 | -$ 0.44 | -$ 0.43 | -$ 0.41 | |
| Feb 27, 2024 | -$ 0.43 | -$ 0.40 | -$ 0.50 | |
| Nov 7, 2023 | -$ 0.43 | -$ 0.39 | -$ 0.51 | |
| Aug 3, 2023 | -$ 0.44 | -$ 0.38 | -$ 0.83 | |
| May 15, 2023 | -$ 0.46 | -$ 0.41 | -$ 0.64 | |
| Mar 9, 2023 | -$ 0.49 | -$ 0.50 | -$ 0.58 | |
| Nov 8, 2022 | -$ 0.61 | -$ 0.51 | -$ 0.57 | |
| Aug 11, 2022 | -$ 0.66 | -$ 0.83 | -$ 0.60 | |
| May 9, 2022 | -$ 0.63 | -$ 0.64 | -$ 0.54 | |
| Mar 3, 2022 | -$ 0.73 | -$ 0.58 | -$ 0.64 |
Fulcrum Therapeutics’s stock was trading at $ 3.74 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, FULC’s price increased to $ 3.77 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.11 | $ 3.74 | $ 3.77 | |
| Jul 30, 2026 | -$ 0.34 | $ 3.62 | $ 3.58 | |
| Apr 27, 2026 | -$ 0.25 | $ 7.84 | $ 7.44 | |
| Feb 24, 2026 | -$ 0.31 | $ 10.89 | $ 8.98 | |
| Oct 29, 2025 | -$ 0.31 | $ 10.00 | $ 8.60 | |
| Jul 29, 2025 | -$ 0.28 | $ 7.81 | $ 6.90 | |
| May 1, 2025 | -$ 0.28 | $ 3.85 | $ 5.62 | |
| Feb 25, 2025 | -$ 0.31 | $ 3.70 | $ 3.32 | |
| Nov 13, 2024 | -$ 0.35 | $ 3.64 | $ 3.32 | |
| Jul 31, 2024 | $ 0.87 | $ 8.41 | $ 9.01 | |
| May 13, 2024 | -$ 0.43 | $ 7.47 | $ 7.91 | |
| Feb 27, 2024 | -$ 0.40 | $ 9.73 | $ 10.32 | |
| Nov 7, 2023 | -$ 0.39 | $ 3.59 | $ 4.17 | |
| Aug 3, 2023 | -$ 0.38 | $ 3.82 | $ 3.95 | |
| May 15, 2023 | -$ 0.41 | $ 3.27 | $ 3.80 | |
| Mar 9, 2023 | -$ 0.50 | $ 6.26 | $ 4.51 | |
| Nov 8, 2022 | -$ 0.51 | $ 5.61 | $ 6.95 | |
| Aug 11, 2022 | -$ 0.83 | $ 7.76 | $ 8.41 | |
| May 9, 2022 | -$ 0.64 | $ 8.63 | $ 7.55 | |
| Mar 3, 2022 | -$ 0.58 | $ 11.10 | $ 13.03 |
Fulcrum Therapeutics released its most recent earnings reports in November 2026, July 2026, April 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Fulcrum Therapeutics missed analysts’ expectations during the last earnings period by
